Citations

Clear

18 citation(s) found for "Sonam, Sonam".

Current practices and trends in surgical decision‐making for children with Lennox–Gastaut syndrome: A cross‐sectional survey by the Pediatric Epilepsy Research Consortium
Chiu, Michelle , Keator, Cynthia, Warren, Aaron E. L. , Knowles, Juliet K. , Samanta, Debopam , Dixon‐Salazar, Tracy , Seinfeld, Syndi, Paolicchi, Juliann , Vidaurre, Jorge , Shellhaas, Renée A. , Clarke, Dave , Bhalla, Sonam , Depositario‐Cabacar, Dewi, Haridas, Babitha , Stafstrom, Carl E. , Erdemir, Gozde , Karakas, Cemal , Chiu, Michelle Y , Koh, Hyun Yong , Vidaurre, Jorge , Patel, Anup D , Loddenkemper, Tobias , Shellhaas, Renée A , Clarke, Dave F , Fine, Anthony , Bhalla, Sonam , Stafstrom, Carl E , Erdemir, Gozde , Karakas, Cemal , Knowles, Juliet K , Patel, Anup D. , Loddenkemper, Tobias , Fine, Anthony L.

Mayo Clinic

Epilepsia Open | September 18, 2025 | Volume: 10 | Issue: 6 | Pages: 1835-1846

10.1002/epi4.70144 | PMID 40965114 Get It

Abstract Objective The objective of this study is to characterize contemporary surgical management practices and factors influencing surgical decision‐making in the management of Lennox–Gastaut Syndrome (LGS) across pediatric epilepsy centers in the United States. Methods A 45‐item cross‐sectional survey was developed and distributed to Pediatric Epilepsy Research Consortium centers. Domains included institutional demographics, surgical evaluation timing and goals, presurgical workup, procedural utilization and outcomes, and barriers to surgery. Descriptive statistics and thematic analysis were performed. Results Thirty‐two pediatric epilepsy centers participated (38% response), the majority comprising pediatric epileptologists at Level 4 National Association of Epilepsy Centers. Most centers (66%) considered surgery after failure of 3–4 antiseizure medications. Presurgical workup typically included brain magnetic resonance imaging (MRI), long‐term electroencephalography (EEG) monitoring, and neuropsychological assessment, while use of functional imaging, magnetoencephalography, and intracranial EEG varied considerably. All centers offered vagus nerve stimulation and corpus callosotomy; 80%–90% offered resection, hemispherectomy, responsive neurostimulation (RNS); 60%–65% offered deep brain stimulation (DBS) and laser ablation. Among centers offering RNS, half targeted thalamic structures exclusively, and the remainder targeted cortical or combined cortical‐thalamic structures; the centromedian nucleus was the preferred thalamic target for RNS and DBS. Surgical decision‐making was influenced by patient characteristics, procedural considerations, and systemic factors. Seizure frequency, family preference, and multidisciplinary input were highly rated across all interventions. Etiology was critical for resection and hemispherectomy, while financial constraints, insurance barriers, and the need for future neuroimaging impacted neuromodulation selection. Scenario‐specific trends included less frequent consideration of DBS and RNS in children under five years, less use of hemispherectomy in older children, preference for corpus callosotomy in children with predominantly drop seizures, and procedural selection based on MRI findings. Significance Substantial variability exists in the surgical management of LGS. These findings highlight critical opportunities to harmonize practices, reduce disparities, and guide comparative effectiveness research to optimize outcomes. Plain Language Summary Lennox–Gastaut Syndrome (LGS) is a severe form of epilepsy that may require surgery when medications are not effective. This study found that surgical care for LGS varies widely across pediatric epilepsy centers in the United States, including when surgery is recommended, how patients are evaluated, and which procedures are available. Newer approaches such as brain stimulation are being used more often, although access remains inconsistent. These findings highlight the need for clearer treatment pathways to ensure that children with LGS have equitable access to the best possible care.
Radiology-Pathology Concordance Conference: Utility and Success in Clinical Practice
Robinson, Kristin A. , Maimone, Santo, Sonam, Sonam, Letter, Haley , Maxwell, Robert W. , Maimone, Santo , Maimone, Santo , Letter, Haley P, Komforti, Miglena K.

Mayo Clinic

Journal of Breast Imaging | August 26, 2025 | Volume: 8 | Issue: 2 | Pages: 190-203

10.1093/jbi/wbaf053 | PMID 41671050 Get It

Abstract The practice of formally documenting radiologic and pathologic concordance after percutaneous breast biopsies was instituted more than 20 years ago. There are several ways in which this can be done, but in many practices the performing radiologist independently compares the imaging findings with the pathology report to determine concordance. However, some studies show that a multidisciplinary review of breast biopsy results can maximize cancer detection, identify discordant cases in a timely manner, decrease imaging follow-up, and avoid unnecessary surgical intervention. This article will propose a practical method to establish a formal radiology-pathology conference in which percutaneous breast biopsies are reviewed with multidisciplinary input to increase efficiency and improve patient care. With the wide implementation of digital radiologic imaging and digital pathology evaluation plus the recent adoption of virtual meeting platforms, a successful radiology-pathology conference can be implemented in nearly any practice setting. Case examples will be presented demonstrating the utility of such a conference.
Integrated Molecular and Clinical Characterization of Pulmonary Large Cell Neuroendocrine Carcinoma
Chiang, Anne C. , Nassar, Amin H. , Kim, Chul , Farhat, Elias Bou , Matteson, Kelsey, Lau, Shun‐Fat , Gallegos, Jesús Antonio Ocejo , Ardeshir‐Larijani, Fatemeh , Leal, Ticiana, Alam, Sumaye, Gray, Jhanelle E. , Hicks, J. Kevin , Kaldas, David , Baena, Javier, Berjaga, María Zurera, Grohé, Christian , Leuders, Heike, Mingo, Emanuele Claudio , Pancirer, Danny, Cheung, Justin M., Lin, Jessica, Watson, Alexander, Camidge, D. Ross , Parikh, Kaushal , Aggarwal, Vanya , Ahmed, Murtaza, Zhang, Jun , Nagasaka, Misako , Awosika, Nichola, Alhamad, Khaled, Zaman, Unaiza, Gupta, Divya , Lau, Chelsea, Khan, Hina, Liauw, Justin , Brown, Tyiesha , Mosteiro, Miguel , Lopes, Gilberto , Patrick, C. , Young, Lauren K. , Aljumaily, Raid, Mirza, Haris , TAKEBE, Y., Baena, Javier , Nassar, Amin H. , Ocejo Gallegos, Jesus Antonio , Bou Farhat, Elias , Espinar, Javier Baena , Adeyelu, Tolulope Tosin , Abushukair, Hassan , Rakaee, Mehrdad , Takabe, Yamato J. , Ramalingam, Suresh S. , Alam, Sumaiya, Nana, Frank Aboubakar , Citarella, Fabrizio , Cortellini, Alessio , Das, Millie , Ellis-Caleo, Timothy John , Linehan, William Marston , Sridhar, Arthi , Crowley, Fionnuala , Marron, Thomas , Sankar, K. Nathan , Kawtharany, Hassan , Owen, Dwight H , Li, Mingjia , Pinato, David J. , Puri, Sonam , Velázquez, Ana I. , Moliner, Laura , Rocha, Pedro , Evans, Mark G. , Vanderwalde, Ari M. , Elliott, Andrew , Nieva, Jorgé , Patrick, C. , Borghaei, Hossein , Lee, Matthew , Kwiatkowski, David J. , Herbst, Roy S. , Flavell, Richard A. , Naqash, Abdul Rafeh

Mayo Clinic

No container title available | May 16, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6639680/v1 Get It

Abstract Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare, aggressive lung tumor marked by significant molecular heterogeneity. In a study of 590 patients across two independent cohorts, we observed comparable overall survival across treatment regimens (chemotherapy, chemoimmunotherapy, immunotherapy) without unexpected adverse events. Genomic analysis identified distinct NSCLC-like (KEAP1, KRAS, STK11 mutations) and SCLC-like (RB1, TP53 mutations) LCNEC subtypes, with 80% aligning with SCLC transcriptional profiles. Serial sampling revealed stable mutational but shifting transcriptomic landscapes over time. NSCLC-like LCNECs showed elevated FGL-1 (a LAG-3 ligand) and SPINK1 expression, while SCLC-like subtypes expressed higher levels of DLL3. Immunofluorescence confirmed FGL-1 in NSCLC-like LCNECs, and H&E slide analyses indicated fewer tumor-infiltrating lymphocytes in LCNECs versus other lung cancers. These findings highlight LCNEC’s distinct immunogenomic profile, supporting future investigations into LAG-3, SPINK1, and DLL3-targeted therapies.
Challenges in Breast Pathology: A Review of the Most Common Problems Encountered in a Subspecialty Consult Service Over 1 Year—Retrospective Review of 553 Specimens
Sonam, Fnu , Downs, Erinn, Rowe, J. Jordi, Hoda, Raza S. , Booth, Christine N. , Duckworth, Lauren A. , Bhattarai, Roshan , Fnu, Sonam , Hoda, Raza S , Duckworth, Ashley L , Komforti, Miglena K. , McIntire, Patrick J.

Mayo Clinic

International Journal of Surgical Pathology | January 3, 2025 | Volume: 33 | Issue: 5 | Pages: 1093-1102

10.1177/10668969241300496 | PMID 39748449 Get It

Aims . To identify the most common reasons for consultation to a large specialty breast pathology service at a major institution. To provide insight into the overall challenges in practicing breast pathology. Methods . The anatomic pathology database at one institution was searched for all breast consultations received in 2021, excluding in-house patients and patients who were transferring care. Results . A total of 553 patients met the criteria ( n = 553) from a variety of academic and private practices. For each patient, the paperwork from the submitting institution was reviewed to identify the specific question, and subsequently classified into 14 categories. The reason for the consultation request was not provided for 78 (14%) patients, and a review of the outside diagnoses, where applicable, was performed. In summary, the top 5 reasons for consultation were: (1) assistance with classification of atypical intraductal epithelial proliferations (32%); (2) evaluation for the presence of (micro-)invasive carcinoma (14%); (3) evaluation of fibroepithelial (12%), (4) papillary (11%), and (5) spindle cell lesions (7%). Conclusion . We show an ongoing educational and practice gap for pathologists who most commonly struggle with classifying atypical precursor lesions, specifically when these are small and focal, or bordering on intraductal carcinoma (32%, 177/553). The second most common reason for consultation was classifying invasive carcinomas as microinvasive and subtypes (total of 20.4%, 113/553). As such, our data supports the continued need for rigid and clear criteria for diagnosing threshold lesions (namely atypical hyperplasias) and intraductal carcinoma of the breast.
Association of nutritional intake with clinical and imaging activity in pediatric multiple sclerosis
Mohan, Sonam D, Peterson, Skyler, Brenton, J. Nicholas , Carmichael, Suzan L. , Virupakshaiah, Akash , Tillema, Jan‐Mendelt , Mar, Soe , Rensel, Mary , Abrams, Aaron , Gorman, Mark , Lotze, Tim, Shukla, Nikita, Graves, Jennifer, Aaen, Gregory , Casper, T. Charles , Rensel, Mary R. , Abrams, Aaron , Chitnis, Tanuja , Brenton, J Nicholas , Virupakshaiah, Akash , Rodriguez, Moses , Benson, Leslie, Waubant, Emmanuelle L.

Mayo Clinic

Multiple Sclerosis Journal | July 30, 2024 | Volume: 30 | Issue: 8 | Pages: 1056-1065

10.1177/13524585241261556 | PMID 39078111 Get It

Background: Understanding nutrition’s role in multiple sclerosis (MS) can guide recommendations and intervention-based studies. Objective: Evaluate the association between nutrition and pediatric-onset MS outcomes. Methods: Prospective longitudinal multicenter study conducted as part of the US Network of Pediatric MS centers. Predictors were collected using a food screener estimating intake of various dietary food groups (e.g. dairy and fruits) and additional calculated indices (e.g. Healthy Eating Index (HEI)). Outcomes included time-from-enrollment to clinical relapse, new magnetic resonance imaging (MRI) T2 lesions, and Expanded Disability Status Scale (EDSS) increase. Results: 353 children with MS were enrolled (mean ± SD age 15.4 ± 2.9, follow-up 3.9 ± 2.6 years). Multivariable analysis demonstrated that increased dairy by 50% of recommended intake was associated with increased relapse risk by 41% (adjusted hazard ratio (HR) 1.41, 95% CI 1.07–1.86), and risk of T2 progression by 40% (1.40, 1.12–1.74). Increased intake of fruit or vegetable above recommended, and every five-point HEI increase decreased relapse risk by 25% (0.75, 0.60–0.95), 45% (0.55, 0.32–0.96), and 15% (0.84, 0.74–0.96), respectively. No associations were found with EDSS. Conclusion: This work supports the influence of dietary intake on MS course, particularly with dairy intake. Future prospective study is required to establish causation.
Overall survival after treatment with CAN-2409 plus valacyclovir in combination with continued ICI in patients with stage III/IV NSCLC with an inadequate response to ICI.
Alesi, Erin R. , Maldonado, Fabien , Mehra, Ranee , Reisenauer, Janani , Swartz, Leigh Klaus , Eapen, George A. , Pichavant, Mina, Nichols, William Garrett, Tak, Paul P., Aggarwal, Charu , Sterman, Daniel H. , Bestvina, Christine M. , Puri, Sonam , Ibrahim, Omar, Duault, Caroline , Valle, Diane M. Del , Gonzalez‐Kozlova, Edgar , Gnjatic, Sacha , Maecker, Holden Terry , Barone, Francesca

Mayo Clinic

Journal of Clinical Oncology | June 26, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 8634-8634

10.1200/jco.2024.42.16_suppl.8634 Get It

8634 Background: Patients with unresectable non-small cell lung cancer (NSCLC) with an inadequate response to immune checkpoint inhibitors (ICI) have limited therapeutic options and expected median overall survival (mOS) of 11.6 to 14.5m (PMID: 35658002 ). The immunosuppressive tumor microenvironment and the lack of a specific T cell response underpin inadequate clinical response. CAN-2409 is a replication-defective adenovirus encoding the HSV-tk gene. Transduced cells activate orally delivered valacyclovir, resulting in immunogenic cell death, and in situ immunization against the patient’s tumor antigens, eliciting a specific immune response against the injected tumor and uninjected metastases. Methods: NCT04495153 is an open-label, phase 2 clinical trial of CAN-2409 + valacyclovir in combination with continued ICI in patients with non-resectable, stage III/IV NSCLC, refractory or resistant to anti-PD-(L)1. Patients were enrolled in 2 cohorts (C) depending on disease status at enrolment: C1, stable disease or C2, progressive disease. Two doses of CAN-2409 (5x1011vp) were given 5-7w apart via bronchoscopic or percutaneous injection into lung tumor, disease-positive lymph node, or peripheral metastasis, each followed by oral prodrug. Patients were assessed for safety, immunologic biomarkers, and OS. Results: As of 16Jan2024, 73 patients were treated (safety population: ≥1 dose of CAN-2409) and 44 were evaluable per protocol (received 2 doses of CAN-2409+ valacyclovir and 12-week CT scan). Baseline treated pt median age was 67 [43-88] yrs, 44% female, 68% on aPD(L)1 alone and 32% aPD(L)1 + pemetrexed regimen. We observed no dose-limiting toxicities or ≥grade 4 treatment-related AEs. mOS of the evaluable population was estimated as 22.0m (95% CI: 14.3m, NA; median follow up (mFU) time of 18.2m). In C2 (n = 38) mOS was 20.6 (mFU 19.2.m) and in C1 (n = 6) was N.A. (mFU 15.2m). mOS in the safety population (n = 73) was 14.3.m (mFU16.8m). 64% of evaluable patients had systemic clinical response with shrinkage of both injected and uninjected lesions. We found a significant correlation between increases in T cell populations after the second injection of CAN-2409 (circulating memory and effector memory CD4+ and CD8+T cells, CD4+ Ki67+IFNg+ and CD4+granzymeB+ T cells, CD8+granzymeB+Ki67+ T cells, T regulatory cells) and subsequent OS (R2 between 0.181 and 0.354 and p = 0.043 and 0.004). Conclusions: Experimental treatment with CAN-2409+valacyclovir in NSCLC pts following an inadequate response to ICI is well tolerated and results in the induction of a cytotoxic and memory circulating T cell response associated with shrinkage of injected and uninjected lesions and a raised tail of the survival curve. mOS of the evaluable population was estimated as 22.0m, markedly longer than the expected mOS of 11.6-14.5m. Clinical trial information: NCT04495153 .
Rare Presentation of Papillary Carcinoma Within a Sentinel Lymph Node in a Patient With Ductal Carcinoma in Situ of the Breast: A Challenging but Useful Case Report Discussion Regarding Displacement or True Metastasis?
Sonam, Fnu , Jakub, James W. , Cornell, Lauren , Robinson, Kristin A. , Komforti, Miglena K. , Jakub, James W , Robinson, Kristin A , Fnu, Sonam , Cornell, Lauren F

Mayo Clinic

International Journal of Surgical Pathology | March 19, 2024 | Volume: 32 | Issue: 8 | Pages: 1588-1594

10.1177/10668969241235316 | PMID 38500348 Get It

Papillary carcinoma of the breast is a rare histologic subtype of invasive breast cancer. In contrast, ductal carcinoma in situ (DCIS) is a noninvasive, nonobligate precursor to invasive mammary carcinoma, confined within the terminal duct lobular unit of the breast and surrounded by an intact myoepithelial cell layer at the stromal/epithelial interface. We present an unusual case in which a patient with only DCIS of the breast exhibited papillary carcinoma within a sentinel lymph node, leading to questions about the origin of the lymph node lesion—whether it represents a true metastasis or iatrogenic displacement during diagnostic procedures. This case underscores the diagnostic challenges and clinical implications associated with such rare presentations.
Solving the mystery of Reed Sternberg like cells in a composite Peripheral T Cell Lymphoma with Epstein Barr Virus and Epstein Barr Virus driven Lymphoproliferative Disorder
Siddiq, M., Shiwlani, Sheena, Ibrar, Warda, Sonam, Fnu , Hashim, M

Mayo Clinic

American Journal of Clinical Pathology | November 29, 2023 | Volume: 160 | Issue: Supplement_1 | Pages: S76-S76

10.1093/ajcp/aqad150.169 Get It

Abstract Introduction/Objective Nodal PTCL with EBV positivity can occasionally contain Reed Sternberg-like cells, and EBV- LPD can mimic Hodgkin lymphoma. Coexistence of these two unusual lymphomas in the same lymph node is very rare. We present a case of a 56-year-old male with Composite EBV+ PTCL NOS and EBV LPD, with positive B-cell gene rearrangement and negative T-cell gene rearrangement presenting a significant diagnostic challenge. Methods/Case Report A 56-year-old male with a history of abdominal tuberculosis presented with lethargy, fatigue, and poor appetite. Physical examination revealed generalized lymphadenopathy. CT scan confirmed lymphadenopathy in bilateral axilla, supraclavicular lymph nodes along with lytic lesions on illiac crest. Ill defined splenic lesions raised concerns for metastasis. Cervical lymph node and bone marrow biopsies were performed. Flow cytometry on the lymph node was not done due to tuberculosis history. Flow cytometry on the bone marrow showed an inverted CD4:CD8 ratio. H&E sections of the lymph node revealed a polymorphic lymphoid infiltrate with prominent Reed Sternberg-like cells. Immunohistochemical staining showed CD30-positive and CD45-negative large cells. T-cell and B-cell gene rearrangements were performed. Initially, B-cell gene rearrangements were positive, while T-gamma was negative. Further testing by IHC and morphological evaluation revealed two distinct cell populations, one with CD3, CD5, and CD7 positivity with partial weak positivity for PD1, CD43, and CD8 and the other consisting of B-cells expressing CD30, EBV, MUM1, and partial expression of BCL6 rare CD79a, and partial weak Pax5. Outside molecular testing showed positive T-cell gene rearrangements. The diagnosis of Composite EBV+ Peripheral T Cell Lymphoma, not otherwise specified, with cytotoxic profile along with EBV driven LPD was made. Bone marrow studies confirmed involvement by the same lymphoma. Results (if a Case Study enter NA) NA Conclusion Identifying EBV-positive Reed Sternberg-like cells in both EBV LPD and PTCL-NOS in a composite lymphoma can be challenging. In the absence of flow cytometry, a composite lymphoma can potentially be misdiagnosed, leading to under-treatment. Repeat testing can be helpful in case of any doubt. Although EBV-positive PTCL with cytotoxic profile and EBV-positive LPD has been reported, the combination of these two lymphomas together is exceedingly rare.
Phase 1 trial of EO2463 peptide‐based immunotherapy as monotherapy and in combination with lenalidomide and rituximab in indolent non‐Hodgkin lymphoma; EONHL1‐20/SIDNEY
Pinto, A. A., Bisneto, J. C. Villasboas, Sanz, R. García, García, Carlos Grande, Smith, Stephen D. , Wallace, D. S., Merryman, R., Marolleau, Jean Pierre, Chêne, Laurent , Fagerberg, Jan, Friedberg, Jonathan W. , Ansel, Sonam , Armand, Philippe , Pinto, A., Bosch, Francesc , Bisneto, J. C. Villasboas, Sanz, R. García, Arcaini, Luca , Marolleau, Jean‐Pierre, Filippi, Rosaria De , Bonny, Christophe , Ansel, S., Zinzani, Pier Luigi

Mayo Clinic

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 581-582

10.1002/hon.3164_435 Get It

CAN-2409 plus prodrug with standard of care immune checkpoint inhibitor for patients with stage III/IV NSCLC.
Maldonado, Fabien , Reisenauer, Janani , Swan, Randy, Caine, Audra, Lopez, Lenika, Manzanera, Andrea G., Nichols, William Garrett, Tak, Paul P., Aggarwal, Charu , Sterman, Daniel H. , Bestvina, Christine M. , Li, Howard Y. , Puri, Sonam , Ibrahim, Omar, Barone, Francesca , Matheny, Christopher Jon

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: TPS9162-TPS9162

10.1200/jco.2023.41.16_suppl.tps9162 Get It

TPS9162 Background: Immune checkpoint inhibitors (ICI) are a standard of care (SOC) treatment that have improved outcomes for patients (pts) with non-small cell lung cancer (NSCLC). However, most pts progress, signaling a need for combination approaches to further improve outcomes. CAN-2409 is a replication-defective adenoviral construct encoding the herpes simplex virus thymidine kinase (HSV-tk) gene that is injected intratumorally followed by 2 weeks of prodrug (valacyclovir or acyclovir). HSV-tk converts the prodrug in the tumor microenvironment into a toxic metabolite, resulting in immunogenic cell death, while the adenoviral proteins provide a strong pro-inflammatory signal. Together, this leads to in situ vaccination against the patient’s own tumor. As a result, CD8+ cytotoxic T cells are educated on how to recognize and kill tumor cells in both the injected tumor and the uninjected metastases. A completed neoadjuvant phase I trial in resectable NSCLC demonstrated safety and immune stimulation (Predina et al 2021), warranting further investigation of CAN-2409 + prodrug as a therapy that can lead to improved long-term outcomes for pts with NSCLC who have a suboptimal response to ICI. Methods: LuTK02 (NCT04495153) is an open-label, multi-arm, phase II clinical trial to evaluate CAN-2409 + prodrug added to SOC ICI (anti-PD-(L)1) therapy in pts with stage III/IV NSCLC presenting with inadequate response (as defined below) to ICI. Cohort 1 includes pts with nonresponding but stable disease ≥18 weeks after starting ICI; cohort 2 includes pts with progressive disease ≥18 weeks after starting ICI. Key eligibility criteria include RECIST-evaluable disease; an injectable lesion (via bronchoscopy or US/IR guidance); ability to continue ICI for the treatment period; no change of ICI or prior interruptions of > 4 weeks within 6 months of enrollment; and no focal therapy at > 3 sites of disease within 12 months prior to enrollment. Key exclusion criteria include a history of ICI immune-related adverse events and known alterations in EGFR, ALK, or ROS1. Eligible patients receive 2 injections of CAN-2409 approximately 6 weeks apart followed by prodrug for 14 days. After treatment of ~40 evaluable pts in cohort 2 with two injections of CAN-2409, the protocol has been amended to include a new cohort (n~20) of pts treated with three injections of CAN-2409 approximately 4 weeks apart, each followed by prodrug for 14 days, to further define the optimal therapeutic regimen. Primary endpoints are overall response and/or disease control rate per RECIST 1.1 criteria and safety of CAN-2409 + prodrug. Secondary endpoints include duration of response, PFS, OS, and biomarker studies. Exploratory endpoints include evaluation of effects in non-injected lesions, changes in non-target (per RECIST) lesions, tumor growth trajectory, and viral shedding. Clinical trial information: NCT04495153 .